SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-052732
Filing Date
2020-11-10
Accepted
2020-11-10 07:20:40
Documents
73
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fulc-10q_20200930.htm 10-Q 3025513
2 EX-10.1 fulc-ex101_12.htm EX-10.1 475734
3 EX-10.2 fulc-ex102_13.htm EX-10.2 40349
4 EX-31.1 fulc-ex311_8.htm EX-31.1 11519
5 EX-31.2 fulc-ex312_9.htm EX-31.2 12327
6 EX-32.1 fulc-ex321_6.htm EX-32.1 6282
7 EX-32.2 fulc-ex322_7.htm EX-32.2 6184
  Complete submission text file 0001564590-20-052732.txt   8549541

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE DOCUMENT fulc-20200930.xml EX-101.INS 1407889
9 XBRL TAXONOMY EXTENSION SCHEMA fulc-20200930.xsd EX-101.SCH 56080
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fulc-20200930_cal.xml EX-101.CAL 51731
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fulc-20200930_def.xml EX-101.DEF 201903
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20200930_lab.xml EX-101.LAB 421528
13 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20200930_pre.xml EX-101.PRE 350076
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38978 | Film No.: 201299618
SIC: 2834 Pharmaceutical Preparations